Hongyun Medical Scientific and Technological

RedCloud Bio, also known as Hongyun Pharma, is a clinical-stage biotechnology company focused on developing next-generation small molecule therapeutics for oncology, particularly targeting drug-resistant mutations. The company leverages an integrated platform that combines structural biology, computational chemistry, and medicinal chemistry to design precision medicines for solid tumors. Its lead candidate, RC0116, is a highly selective EGFR inhibitor designed to address complex mutations such as L858R/T790M/C797S in non-small cell lung cancer. With R&D operations in both Hangzhou, China, and the San Francisco Bay Area, RedCloud Bio aims to provide effective treatments for patients who have failed existing tyrosine kinase inhibitor therapies.